SNHD expanding offerings of new Covid medication

Paxlovid used on those with mild to moderate symptoms
Medical syringes with inscription Paxlovid for Covid-19 treatment
Paxlovid Photo credit Evgeny Lonskov/Getty Images

Las Vegas, NV (KXNT) - Last week, the Southern Nevada Health District received 120 treatment courses of the COVID-19 medication, Paxlovid and began offering the treatment to patients who test positive, are symptomatic, over the age of 65, and meet the criteria for taking the medication.

Live On-Air
Ask Your Smart Speaker to Play News Talk Eight Fourty A M K X N T
News and Talk Radio 840 AM
Listen Now
Now Playing
Now Playing

This week, the SNHD announced that accessibility to Paxlovid treatment is being expanded to include people 12 to 64 years of age with a positive COVID-19 test who are at higher risk for severe illness.

People in this group must also have symptoms of COVID-19, and those symptoms must have started within the last five days. A complete list of conditions included in the criteria is available on the Health District’s website at www.snhd.info/paxlovid.

Paxlovid is a new oral medication to treat mild-to-moderate COVID-19 disease in adults and children 12 years of age and older who are at higher risk for progressing to severe illness, including hospitalization and death. The therapeutic received emergency use authorization from the U.S. Food and Drug Administration in December 2021. A study found that Paxlovid reduced the chance of hospitalization or death by 88 percent. People must start taking the medication within five days of when their symptoms began.

People who may meet the criteria and are interested in testing and screening for eligibility will need to get tested at the Health District’s clinic at its main public health center located at 280 S. Decatur Blvd. Appointments are available at www.SNHD.info/covid-testing.